BioCryst Pharmaceuticals Inc at JPMorgan Healthcare Conference Transcript
Great. Good afternoon, everyone. My name is Jess Fye. I'm one of the biotech analysts at JPMorgan, and we're continuing the 2020 Healthcare Conference today with BioCryst. We're going to do a Q&A session with the management team right after this. It's just down the hall in the Yorkshire Room, so you can follow me over there if you want to hear more. But for the presentation, I'm going to turn it over to the company's CEO, Jon Stonehouse.
Thank you, Jess. Thanks for the invite to this year's J.P. Morgan Healthcare Conference, and good afternoon.
I'm going to be making some forward-looking statements. Those statements have risks and our risk factors can be found on our website listed on the bottom of Slide 2.
So what makes us different at BioCryst is bringing forward oral drugs for patients with rare disease. When I -- when we first started talking about this, I thought of it as some
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
